Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages

Key Points

• Analysts have given Tenaya Therapeutics, Inc. (NASDAQ:TNYA) an average rating of "Buy", with six firms recommending the stock.
• The average twelve-month price target from broker reports for TNYA is $6.25, while recent target prices include $9.00 from Chardan Capital and $5.00 from HC Wainwright.
• As of now, TNYA's shares have a market capitalization of $229.80 million and have shown significant volatility, with a 52-week trading range between $0.36 and $4.01.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month price objective among analysts that have covered the stock in the last year is $6.25.

Several research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a report on Tuesday, September 2nd. Wall Street Zen upgraded Tenaya Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Tenaya Therapeutics in a report on Thursday, August 7th.

Hedge Funds Weigh In On Tenaya Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. DAFNA Capital Management LLC purchased a new stake in shares of Tenaya Therapeutics during the 1st quarter valued at $27,000. Woodline Partners LP bought a new position in Tenaya Therapeutics in the fourth quarter valued at $28,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Tenaya Therapeutics during the first quarter valued at about $33,000. CWM LLC lifted its stake in Tenaya Therapeutics by 14,231.7% during the first quarter. CWM LLC now owns 71,945 shares of the company's stock worth $41,000 after purchasing an additional 71,443 shares during the last quarter. Finally, Callan Family Office LLC purchased a new position in shares of Tenaya Therapeutics in the 1st quarter worth about $50,000. Hedge funds and other institutional investors own 90.54% of the company's stock.

Tenaya Therapeutics Stock Performance

Tenaya Therapeutics stock traded down $0.03 during mid-day trading on Friday, reaching $1.39. The company's stock had a trading volume of 353,489 shares, compared to its average volume of 2,978,926. The firm's fifty day moving average price is $1.01 and its two-hundred day moving average price is $0.71. Tenaya Therapeutics has a 12-month low of $0.36 and a 12-month high of $4.01. The company has a market capitalization of $225.73 million, a P/E ratio of -1.44 and a beta of 3.06.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. On average, research analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.